Belinostat

Generic Name: Belinostat

Brand Names: Beleodaq

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₄N_₂O_₄S

CAS Number: 866323-14-0

Unique Ingredient Identifier: F4H96P17NZ

Background: Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies for th...

Indication: Belinostat is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) with manageable safety profile. It is a potential alternative therapy for patients who did not experience adequate response to first-line drugs for PTCL. It can be used in patients with baseline thrombocytopenia .

Associated Conditions: Refractory Peripheral T-Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma

Associated Therapies: -

Clinical Trials

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Phase 3

Recruiting

Conditions: Systemic Anaplastic Large Cell Lymphoma
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Angioimmunoblastic T-cell Lymphoma
Lymphoma, T-Cell, Peripheral
Follicular T-Cell Lymphoma
Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
Lymphoma, T-Cell

Interventions: Drug: Soquelitinib
Drug: Belinostat
Drug: Pralatrexate

First Posted Date: 2024-08-19

Last Posted Date: 2024-10-21

Lead Sponsor: Corvus Pharmaceuticals, Inc.

Target Recruit Count: 150

Registration Number: NCT06561048

Locations: 🇺🇸
Corvus Clinical Trials Information, Burlingame, California, United States

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

Phase 2

Not yet recruiting

Conditions: Carcinoma, Neuroendocrine
Tumor, Neuroendocrine
Tumors, Neuroendocrine
Neuroendocrine; Carcinoma
Small Cell; Receptors

Interventions: Drug: Belinostat
Drug: Cisplatin
Drug: Etoposide

First Posted Date: 2024-05-09

Last Posted Date: 2024-12-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT06406465

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

Phase 1

Recruiting

Conditions: Refractory Transformed Non-Hodgkin Lymphoma
Recurrent B-Cell Non-Hodgkin Lymphoma
Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Refractory Non-Hodgkin Lymphoma
Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Recurrent T-Cell Non-Hodgkin Lymphoma
Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
Recurrent Non-Hodgkin Lymphoma
Recurrent Transformed Non-Hodgkin Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type

Interventions: Drug: Belinostat
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Other: Pharmacokinetic Study
Procedure: Positron Emission Tomography and Computed Tomography Scan
Drug: Tazemetostat

First Posted Date: 2022-11-25

Last Posted Date: 2024-10-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 64

Registration Number: NCT05627245

Locations: 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
University of Kansas Clinical Research Center, Fairway, Kansas, United States

and more 7 locations

Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

Phase 2

Recruiting

Conditions: Metastatic Uveal Melanoma

Interventions: Drug: Binimetinib
Drug: Belinostat

First Posted Date: 2021-12-27

Last Posted Date: 2024-12-12

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 32

Registration Number: NCT05170334

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in ARID1A Mutated Cancer Focus on Urothelial Carcinoma

Phase 1

Suspended

Conditions: Infiltrating Urothelial Carcinoma, Sarcomatoid Variant
Locally Advanced Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Unresectable Urothelial Carcinoma

Interventions: Drug: Belinostat
Biological: Durvalumab

First Posted Date: 2021-12-13

Last Posted Date: 2024-06-18

Lead Sponsor: University of Utah

Target Recruit Count: 9

Registration Number: NCT05154994

Locations: 🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States

Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL

Phase 2

Recruiting

Conditions: PTCL

Interventions: Drug: Azacytidine
Drug: Romidepsin
Drug: Belinostat
Drug: Pralatrexate
Drug: Gemcitabine

First Posted Date: 2021-02-10

Last Posted Date: 2024-08-07

Lead Sponsor: University of Virginia

Target Recruit Count: 50

Registration Number: NCT04747236

Locations: 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
University of Virginia, Charlottesville, Virginia, United States

and more 2 locations

Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

Phase 1

Active, not recruiting

Conditions: Metastatic Breast Cancer
Metastatic Castration-resistant Prostate Cancer
Metastatic Ovarian Carcinoma

Interventions: Drug: Talazoparib
Drug: Belinostat

First Posted Date: 2021-01-11

Last Posted Date: 2024-11-05

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 26

Registration Number: NCT04703920

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

Phase 2

Active, not recruiting

Conditions: Metastatic Primary Central Chondrosarcoma
Locally Advanced Unresectable Primary Central Chondrosarcoma
Unresectable Primary Central Chondrosarcoma

Interventions: Drug: Belinostat
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Decitabine and Cedazuridine
Drug: Guadecitabine
Procedure: Magnetic Resonance Imaging

First Posted Date: 2020-04-10

Last Posted Date: 2024-12-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 32

Registration Number: NCT04340843

Locations: 🇺🇸
UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
HaysMed, Hays, Kansas, United States

and more 36 locations